Solventum Corporation (SOLV) P/E Ratio History
UndervaluedTrading at 8.8x vs 5Y avg 17.1x · 33th percentile · Below historical baseline · Data 2024–2026
Loading P/E history...
P/E Ratio Analysis
As of July 7, 2026, Solventum Corporation (SOLV) trades at a price-to-earnings ratio of 8.8x, with a stock price of $77.94 and trailing twelve-month earnings per share of $8.16.
The current P/E is 49% below its 5-year average of 17.1x. Over the past five years, SOLV's P/E has ranged from a low of 8.0x to a high of 35.0x, placing the current valuation at the 33th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.5x, SOLV trades at a 63% discount to its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 199.4x.
Relative to the broader market, SOLV trades at a notable discount to the S&P 500 median P/E of 25.6x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SOLV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SOLV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
SOLV P/E vs Peers
Healthcare staffing and facility services peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $56B | 26.7 | 1.61Best | -1% | |
| $14B | 38.8 | - | -5% | |
| $17B | 30.5 | - | -25% | |
| $10B | 26.5 | 8.40 | +7% | |
| $120B | 37.3 | 2.51 | +8% | |
| $18B | 25.3Lowest | - | -20% | |
| $28B | 34.6 | 3.31 | +47%Best | |
| $13B | 33.3 | - | +1% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
SOLV Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $65.30 | $8.17 | 8.0x | -53% |
| FY2025 Q4 | Dec 31 2025 | $79.24 | $8.88 | 8.9x | -48% |
| FY2025 Q3 | - | $73.00 | $8.69 | 8.4x | -51% |
| FY2025 Q2 | Jun 30 2025 | $75.84 | $2.17 | 34.9x | +104% |
| FY2025 Q1 | Mar 31 2025 | $76.04 | $2.17 | 35.0x | +105% |
| FY2024 Q4 | - | $66.06 | $2.76 | 23.9x | +40% |
| FY2024 Q3 | Sep 30 2024 | $69.72 | $4.15 | 16.8x | -2% |
| FY2024 Q2 | Jun 30 2024 | $52.88 | $6.12 | 8.6x | -49% |
| FY2024 Q1 | Mar 31 2024 | $69.55 | $7.47 | 9.3x | -46% |
Average P/E for displayed period: 17.1x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
2+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SOLV — Frequently Asked Questions
Quick answers to the most common questions about buying SOLV stock.
What is SOLV's P/E ratio?
Solventum Corporation (SOLV) trailing twelve-month P/E ratio is 8.8x, based on TTM diluted EPS of $8.16. The 5-year average P/E is 17.1x and the historical range spans 8.0x to 35.0x.
Is SOLV stock overvalued or undervalued?
SOLV trades at 8.8x P/E, below its 5-year average of 17.1x. At the 33th percentile of its historical range (8.0x–35.0x), the stock is priced at a discount to its own history.
Is SOLV stock expensive?
No, SOLV is not expensive on a historical basis. The current P/E of 8.8x is below the 5-year average of 17.1x and sits at the 33th percentile of its valuation range.
What is SOLV's historical P/E range?
Over the past 5 years, SOLV's P/E ratio has ranged from 8.0x to 35.0x, with a median of 9.3x and an average of 17.1x. The current P/E of 8.8x places the stock at the 33th percentile of this range. Full historical data spans 2024–2026.
How does SOLV's P/E compare to the S&P 500?
SOLV trades at 8.8x P/E versus the S&P 500 median of 25.6x. The 66% discount to the market suggests lower growth expectations or perceived higher risk.
How does SOLV's valuation compare to Healthcare peers?
Solventum Corporation P/E of 8.8x compares to the Healthcare sector median of 23.5x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is SOLV's PEG ratio?
SOLV PEG ratio is N/A, based on a P/E of 8.8x and EPS growth of 221.7%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is SOLV's earnings yield?
SOLV earnings yield is 11.39%, the inverse of its 8.8x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.